Provided by Tiger Trade Technology Pte. Ltd.

Harrow Health Inc

30.61
-0.1900-0.62%
Post-market: 30.860.2522+0.82%18:44 EDT
Volume:596.87K
Turnover:18.31M
Market Cap:1.15B
PE:-30.63
High:31.10
Open:30.55
Low:30.28
Close:30.80
52wk High:54.85
52wk Low:28.54
Shares:37.49M
Float Shares:28.93M
Volume Ratio:1.18
T/O Rate:2.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9993
EPS(LYR):-0.1400
ROE:-116.07%
ROA:-0.45%
PB:75.49
PE(LYR):-218.64

Loading ...

Harrow to Present Phase 3 Byqlovi Post-Cataract Inflammation Trial Data at AAO 2026

Reuters
·
Sep 30

Craig-Hallum Keeps Their Buy Rating on Harrow Health (HROW)

TIPRANKS
·
Sep 30

Leerink Partners Initiates Coverage on Harrow With Outperform Rating, $45 Price Target

MT Newswires Live
·
Sep 09

Harrow initiated with an Outperform at Leerink

TIPRANKS
·
Sep 09

Harrow CFO Andrew Boll Takes on Principal Accounting Officer Role After Pollard Exit

Reuters
·
Sep 05

Harrow (HROW) Dropped, So What Is Behind The Latest Attention?

Simply Wall St.
·
Aug 28

Analysts’ Top NA Picks: Harrow Health (HROW), Boost Run (BRUN)

TIPRANKS
·
Aug 26

Analysts’ Top NA Picks: Harrow Health (HROW), Scribe Therapeutics Inc. (SCTX)

TIPRANKS
·
Aug 20

Analysts Have Conflicting Sentiments on These NA Companies: Harrow Health (HROW) and Lineage, Inc. (LINE)

TIPRANKS
·
Aug 20

Harrow's IHEEZO Cuts Patient-Reported Discomfort 58% in Intravitreal-Injection Study

MT Newswires Live
·
Aug 20

Harrow Announces Iheezo® Data in Patient-Reported Discomfort Following Intravitreal Injections

THOMSON REUTERS
·
Aug 20

Harrow: Single-Center, Investigator-Initiated Study Demonstrated Statistically Significant Differences Favoring Iheezo at Every Measured Time Point

THOMSON REUTERS
·
Aug 20

Harrow - Iheezo Associated with Lower Patient-Reported Discomfort at All Post-Injection Assessments

THOMSON REUTERS
·
Aug 20

Harrow Says Iheezo Trial Shows 58% Lower Discomfort than Proparacaine After Intravitreal Injections

Reuters
·
Aug 20

Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In?

Simply Wall St.
·
Aug 20

Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy?

Simply Wall St.
·
Aug 18

Harrow Chief Scientific Officer Amir Shojaei Disposes of 11,250 Common Shares Worth $450,000

Reuters
·
Aug 18

Harrow Price Target Maintained with a $63.00/Share by BTIG

Dow Jones
·
Aug 12

Harrow, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Harrow Q2 Swings to Loss, Revenue Rises

MT Newswires Live
·
Aug 11